Nephrotic syndrome in infants and toddlers before and after introduction of the meningococcal B vaccine programme in England: An ecological study |
| |
| Affiliation: | 1. Public Health England, London, UK;2. London School of Hygiene and Tropical Medicine, London, UK;1. Istituto Giannina Gaslini, Genova, Italy;2. University of Parma, Parma, Italy;1. Department of Pediatrics, Children’s Hospital of Geneva, University Hospitals of Geneva, Geneva, Switzerland;2. Pediatric Infectious Diseases Unit, Department of Pediatrics, Children’s Hospital of Geneva, University Hospitals of Geneva, Geneva, Switzerland;3. Romand Unit of Pediatric Nephrology, Department of Pediatrics, University Hospitals of Geneva and Lausanne, Switzerland;4. Department of Pediatrics, University Hospital of Basel, Basel, Switzerland;5. Platform of Clinical Research in Pediatrics, Department of Pediatrics, University Hospitals of Geneva, Geneva, Switzerland;6. Department of Pathology, University of Geneva, Faculty of Medicine and World Health Organization Collaborating Center for Vaccinology and Neonatal Immunology, Geneva, Switzerland;1. University of Tampere Medical School, Tampere, Finland;2. University Hospital Hradec Kralove, Hradec Kralove, Czech Republic;3. Novartis Vaccines and Diagnostics S.r.l., Siena, Italy;4. Novartis Vaccines and Diagnostics, Cambridge, MA, United States;1. 1st Department of Pediatrics, Infectious Diseases Unit, “Aghia Sophia” Children''s Hospital, Athens University School of Medicine, Athens, Greece;2. Department of Nephrology, “P. and A. Kyriakou” Children''s Hospital, Athens, Greece |
| |
| Abstract: | A possible increased risk of nephrotic syndrome (NS) following a meningococal group B vaccination campaign was identified during active safety surveillance in a province in Quebec, Canada where 4 cases were reported from an exposed population of ~490,000, a higher rate than in provinces not using the vaccine. Meningococcal B vaccine has been given routinely at 2, 4 and 12 months of age in the United Kingdom since September 2015. To investigate the Canadian signal we used English hospital admissions data from 2005 to 2019 in 2–23 month old children to determine whether the rate of NS changed following the introduction of the vaccine. The analysis was stratified by age 2–5 months, 6–11 months, 12–17 months and 18–23 months. The results showed no evidence of an increased risk with incidence rate ratios between 0.81 (95% confidence interval 0.56–1.19) for age 6–11 months and 1.18 (0.84–1.66) for age 12–17 months. |
| |
| Keywords: | Meningococcal B vaccine Nephrotic syndrome Ecological Vaccine safety |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
